Read, Watch or Listen

US health authorities advise against the Chikungunya vaccine, Ixchiq, for Americans aged 60 and older due to a potential link between the vaccine and serious side effects like heart and brain complications in older individuals. This follows an investigation into several cases of such adverse reactions. The CDC and FDA have issued warnings, while European regulators are also examining the issue. A recommendation for an alternative vaccine, Vimkunya, for those aged 12 and older traveling to affected regions is under consideration.

Prepared by Olivia Bennett and reviewed by editorial team.